Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 27Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 21Cisplatin 15Docetaxel 14Bevacizumab 14Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Irinotecan 11Fluorouracil 11Afatinib 10eribulin 9BI 6727 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × remetinostat × Tumor-Agnostic × Clear all
NCT03875859 2021-05-20

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Stanford University

Phase 2 Terminated
4 enrolled 9 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡